Skip to main content Accessibility help
×
Home

Effect of TGF-β1 polymorphism on the susceptibility to schizophrenia and treatment response to atypical antipsychotic agent

  • Hwa-Young Lee (a1) and Yong-Ku Kim (a1) (a2)

Abstract

Lee H-Y, Kim Y-K. Effect of TGF-β1 polymorphism on the susceptibility to schizophrenia and treatment response to atypical antipsychotic agent.

Objective:

Several studies have suggested that cytokine alterations could be related to the pathophysiology of schizophrenia. Transforming growth factor-beta1 (TGF-β1) is believed to be an important factor in regulation of inflammatory responses and to have anti-inflammatory effects. TGF-β1 also has trophic effects on dopaminergic neurons. We tested the hypothesis TGF-β1 is associated with the pathophysiology of schizophrenia.

Methods:

The polymorphisms at codon 10 (T869C) and codon 25 (G915C) of TGF-β1 were analysed in 99 schizophrenia patients and 130 normal controls. At baseline and after 8 weeks of treatment, clinical symptoms were evaluated on Positive and Negative Syndrome Scale (PANSS).

Results:

None of the subjects were polymorphic at codon 25. However, the C allele at codon 10 was more frequent in schizophrenia (p = 0.05). Although schizophrenia group showed a higher tendency of allele frequency in the subjects with C allele (p = 0.05), the allelic difference did not reach statistical significance after correction for multiple comparisons (p = 0.1).

PANSS scores showed no significant correlation with genotypes. The genotype distribution was not significantly different between responders and non-responders. However, the C allele was more frequent among responders (p = 0.03).

Conclusion:

These results suggest that the TGF-β1 polymorphism is associated with therapeutic response to antipsychotics. However, further studies with larger numbers of subjects are needed to confirm the effect of TGF-β1 in schizophrenia.

Copyright

Corresponding author

Yong-Ku Kim, Department of Psychiatry, College of Medicine, Korea University Ansan Hospital, Ansan City, Gojan Dong, 516, Kyunggi Province 425-020, Korea. Tel: +82 31 412 5140; Fax: +82 31 412 5144; E-mail: yongku@korea.ac.kr

References

Hide All
1.Dunn, AJ, Wang, J, Ando, T.Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999;461:117127.
2.Leonard, BE.Changes in the immune system in depression and dementia: causal or co-incidental effects? Int J Dev Neurosci 2001;19:305312.
3.Krieglstein, K, Suter-Crazzolara, C, Fischer, WH, Unsicker, K.TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J 1995;14:736742.
4.Krieglstein, K, Unsicker, K.Transforming growth factor-beta promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity. Neuroscience 1994;63:11891196.
5.Zhang, L, Yi, H, Xia, XP, Zhao, Y.Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance. Autoimmunity 2006;39:269276.
6.Schmitt, E, Hoehn, P, Huels, Cet al. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol 1994;24:793798.
7.Prud’homme, GJ, Piccirillo, CA.The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 2000;14:2342.
8.Barral-Netto, M, Barral, A, Brownell, CEet al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992;257:545548.
9.Lindholm, D, Castren, E, Kiefer, R, Zafra, F, Thoenen, H.Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 1992;117:395400.
10.Logan, A, Berry, M.Transforming growth factor-beta 1 and basic fibroblast growth factor in the injured CNS. Trends Pharmacol Sci 1993;14:337342.
11.Wahl, SM, Allen, JB, Mccartney-Francis, Net al. Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 1991;173:981991.
12.Horst, HA, Scheithauer, BW, Kelly, PJ, Kovach, JS.Distribution of transforming growth factor-beta 1 in human astrocytomas. Hum Pathol 1992;23:12841288.
13.Morganti-Kossmann, MC, Kossmann, T, Wahl, SM.Cytokines and neuropathology. Trends Pharmacol Sci 1992;13: 286291.
14.Fujii, D, Brissenden, JE, Derynck, R, Francke, U.Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 1986;12:281288.
15.Francks, C, Tozzi, F, Farmer, Aet al. Population-based linkage analysis of schizophrenia and bipolar case-control cohorts identifies a potential susceptibility locus on 19q13. Mol Psychiatry 2008 [E-pub ahead of print].
16.Cambien, F, Ricard, S, Troesch, Aet al., The Etude Cas-Temoin de l’Infarctus du Myocarde (ECTIM) Study. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. Hypertension 1996;28:881887.
17.Hutchinson, IV, Turner, DM, Sankaran, D, Awad, MR, Sinnott, PJ.Influence of cytokine genotypes on allograft rejection. Transplant Proc 1998;30:862863.
18.Awad, MR, El-Gamel, A, Hasleton, P, Turner, DM, Sinnott, PJ, Hutchinson, IV.Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:10141020.
19.Blobe, GC, Schiemann, WP, Lodish, HF.Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:13501358.
20.Vawter, MP, Dillon-Carter, O, Issa, F, Wyatt, RJ, Freed, WJ.Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology 1997;16:8387.
21.Vawter, MP, Dillon-Carter, O, Tourtellotte, WW, Carvey, P, Freed, WJ.TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol 1996;142:313322.
22.Lee, KM, Kim, YK.The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006;6:12981304.
23.Kim, YK, Myint, AM, Lee, BHet al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004;129:267272.
24.Na, KS, Kim, YK.Monocytic Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007;56:5563.
25.Kim, YK, Kim, L, Lee, MS.Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000;44:165175.
26.Kim, YK, Lee, MS, Suh, KY.Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 1998;43:701704.
27.Kim, YK, Myint, AM, Lee, BHet al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:11291134.
28.Woods, SW.Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64: 663667.
29.Grainger, DJ, Heathcote, K, Chiano, Met al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999;8: 9397.
30.Suthanthiran, M, Li, B, Song, JOet al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000;97: 34793484.
31.Sugiura, Y, Niimi, T, Sato, Set al. Transforming growth factor beta1 gene polymorphism in rheumatoid arthritis. Ann Rheum Dis 2002;61:826828.
32.Yamada, Y, Miyauchi, A, Goto, Jet al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998;13:15691576.
33.Yokota, M, Ichihara, S, Lin, TL, Nakashima, N, Yamada, Y.Association of a T29–>C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:27832787.
34.Li, B, Khanna, A, Sharma, V, Singh, T, Suthanthiran, M, August, P.TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999;33:271275.
35.Mors, O, Mortensen, PB, Ewald, H.A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophr Res 1999;40:6774.
36.Leucht, S, Burkard, T, Henderson, J, Maj, M, Sartorius, N.Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317333.
37.Oken, RJ, Schulzer, M.At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull 1999;25:625638.
38.Lee, EB, Kim, JY, Lee, YJ, Abdallah, A, Lympany, P, Song, YW.Transforming growth factor-beta1 polymorphisms in Korean patients with systemic sclerosis. Tissue Antigens 2004;63:491495.
39.Kim, Y, Lee, C.The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke 2006;37:28432845.
40.Lympany, PA, Avila, JJ, Mullighan, C, Marshall, S, Welsh, KI, Du Bois, RM.Rapid genotyping of transforming growth factor beta1 gene polymorphisms in a UK Caucasoid control population using the polymerase chain reaction and sequence-specific primers. Tissue Antigens 1998;52:573578.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed